JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Iron-engineered mesoporous silica nanocatalyst with biodegradable and catalytic framework for tumor-specific therapy.

Biomaterials 2018 May
Inorganic mesoporous silica-based nanovehicles are highly promising for drug delivery but still suffer from the disadvantages of lacking functionality and poor biodegradability on account of the inert silica framework. Moreover, conventional cancer therapeutics typically employ toxic anticancer drugs or invasive external irradiations, which will inevitably give rise to severe adverse effects and diminished therapeutic outcome. In this work, we report on the iron engineered framework of mesoporous silica nanoparticles (MSNs) to fabricate a nanocatalyst with biodegradable and catalytic framework via a "dissolution-regeneration" strategy (designated as rFeOx -HMSN). Based on the abundant overexpressed hydrogen peroxide (H2 O2 ) and mild acidic nature in tumor microenvironment (TME), rFeOx -HMSN nanocatalyst could trigger in-situ Fenton-like reactions to produce highly toxic hydroxyl radicals (·OH), causing remarkable oxidative damages against tumor cells/xenografts. Additionally, the iron-engineered rFeOx -HMSN nanocatalyst could readily collapse via an iron-extraction strategy under protein-rich environment, thereby improving the biodegradability of rFeOx -HMSN nanocatalyst. This work paves a promising way to engineer the inert framework of MSN into functional, biodegradable and catalytic nanoplatform, featuring effective tumor-therapeutic outcome and stimuli-responsive biodegradation concurrently.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app